• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.出血性疾病长期治疗的病原体安全性：仍与当前实践相关。
Haematologica. 2013 Oct;98(10):1495-8. doi: 10.3324/haematol.2013.084145.
2
From the Centers for Disease Control and Prevention. Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.来自疾病控制与预防中心。美国1998年5月至2002年6月出血性疾病患者的血液安全监测。
JAMA. 2003 Feb 5;289(5):541-3.
3
Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.1998年5月至2002年6月美国出血性疾病患者的血液安全监测
MMWR Morb Mortal Wkly Rep. 2003 Jan 3;51(51-52):1152-4.
4
Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?用于治疗出血性疾病的产品的病原体去除/灭活：有哪些工艺，我们应该对患者说些什么？
Ann Hematol. 2017 Aug;96(8):1253-1270. doi: 10.1007/s00277-017-3028-4. Epub 2017 Jun 18.
5
Studies on the effect of fresh blood transfusions and normal human plasma, dried, (single donor, antihemophilic) infusions on hemophilia and hemophilia-like diseases.关于新鲜输血以及冻干正常人血浆（单一供血者，抗血友病）输注对血友病及类血友病疾病影响的研究。
Bibl Haematol. 1962;13:413-6. doi: 10.1159/000426461.
6
[Current status of the preparation and use of antihemophilic fractions in France. (Their use in surgery in hemophilia)].[法国抗血友病因子制剂的制备与使用现状。（其在血友病手术中的应用）]
Transfusion (Paris). 1966;9(3):237-44.
7
[Indications for blood derivatives in hemorrhagic syndromes (excluding thrombopenia)].[出血综合征（不包括血小板减少症）中血液衍生物的适应症]
Sang. 1956;27(1):39-59.
8
Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats.出血性疾病长期治疗的病原体安全性：（不可）预测的风险和不断演变的威胁。
Semin Thromb Hemost. 2013 Oct;39(7):779-93. doi: 10.1055/s-0033-1354420. Epub 2013 Sep 12.
9
[On the therapy of congenital hemorrhagic diatheses].[论先天性出血性素质的治疗]
Med Welt. 1968 May 18;20:1315-7.
10
Diagnosis and management of bleeding disorders.出血性疾病的诊断与管理
Anesthesiology. 1977 Aug;47(2):171-80. doi: 10.1097/00000542-197708000-00008.

引用本文的文献

1
Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine.基于代谢组学的检测面临的挑战、代谢组学分析揭示的生物标志物，以及代谢组学在精准医学中应用的前景。
Int J Mol Sci. 2022 May 6;23(9):5213. doi: 10.3390/ijms23095213.
2
Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?用于治疗出血性疾病的产品的病原体去除/灭活：有哪些工艺，我们应该对患者说些什么？
Ann Hematol. 2017 Aug;96(8):1253-1270. doi: 10.1007/s00277-017-3028-4. Epub 2017 Jun 18.
3
Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.血管性血友病及罕见出血性疾病的诊断与治疗
J Clin Med. 2017 Apr 10;6(4):45. doi: 10.3390/jcm6040045.
4
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.重组凝血因子IX每周一次预防性给药可提高B型血友病患者的依从性。
J Blood Med. 2016 Nov 30;7:275-282. doi: 10.2147/JBM.S84597. eCollection 2016.
5
Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.婴儿期（出生后前两年）血友病的并发症：来自疾病控制与预防中心通用数据收集系统的报告
Haemophilia. 2017 Mar;23(2):207-214. doi: 10.1111/hae.13081. Epub 2016 Nov 4.
6
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.人血管性血友病因子/凝血因子VIII浓缩物在儿童血管性血友病/血友病A患者管理中的应用
Ther Clin Risk Manag. 2016 Jun 30;12:1029-37. doi: 10.2147/TCRM.S87543. eCollection 2016.
7
Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.预防通过血液/血浆衍生产品传播病原体以治疗出血性疾病的当前概念。
Blood Rev. 2016 Jan;30(1):35-48. doi: 10.1016/j.blre.2015.07.004. Epub 2015 Jul 20.
8
Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.重组血管性血友病因子在重度血管性血友病中的止血疗效、安全性及药代动力学
Blood. 2015 Oct 22;126(17):2038-46. doi: 10.1182/blood-2015-02-629873. Epub 2015 Aug 3.
9
Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.人细小病毒B19与血液制品安全：二十年改进历程
Blood Transfus. 2015 Apr;13(2):184-96. doi: 10.2450/2014.0174.14.
10
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.意大利血友病及先天性出血性疾病的治疗原则与管理建议更新
Blood Transfus. 2014 Oct;12(4):575-98. doi: 10.2450/2014.0223-14.

本文引用的文献

1
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening.在核酸检测筛查时代，接受血浆衍生因子浓缩物治疗的出血性疾病患者中，细小病毒 B19 传播的证据。
Transfusion. 2013 Jun;53(6):1217-25. doi: 10.1111/j.1537-2995.2012.03907.x. Epub 2012 Sep 24.
2
Imiglucerase in the treatment of Gaucher disease: a history and perspective.伊米苷酶治疗戈谢病：历史与展望
Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18.
3
How we choose factor VIII to treat hemophilia.我们如何选择因子 VIII 治疗血友病。
Blood. 2012 May 3;119(18):4108-14. doi: 10.1182/blood-2012-01-394411. Epub 2012 Mar 12.
4
Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients.成人血友病患者的非致命性心血管疾病、恶性肿瘤和其他合并症。
Thromb Res. 2012 Aug;130(2):157-62. doi: 10.1016/j.thromres.2011.12.012. Epub 2011 Dec 30.
5
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.新型 HBsAg 标志物与隐匿性乙型肝炎病毒感染密切相关，并强烈影响 HBsAg 的检测。
Antiviral Res. 2012 Jan;93(1):86-93. doi: 10.1016/j.antiviral.2011.10.022. Epub 2011 Nov 9.
6
Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.既往未接受治疗的重度 A 型血友病患者使用血浆源性与重组凝血因子 VIII 浓缩物治疗的累积抑制剂发生率：一项关键性系统评价。
Crit Rev Oncol Hematol. 2012 Jan;81(1):82-93. doi: 10.1016/j.critrevonc.2011.01.002. Epub 2011 Jan 31.
7
Assessing emerging infectious threats to blood safety for the blood disorders community.评估新兴传染病对血液疾病患者群体的血液安全威胁。
Am J Prev Med. 2010 Apr;38(4 Suppl):S468-74. doi: 10.1016/j.amepre.2009.12.019.
8
Mortality and causes of death in Italian persons with haemophilia, 1990-2007.意大利血友病患者 1990-2007 年的死亡率和死因。
Haemophilia. 2010 May;16(3):437-46. doi: 10.1111/j.1365-2516.2009.02188.x. Epub 2010 Feb 9.
9
HLA-B27 and host-pathogen interaction.人类白细胞抗原B27与宿主-病原体相互作用
Adv Exp Med Biol. 2009;649:235-44. doi: 10.1007/978-1-4419-0298-6_17.
10
Emerging and re-emerging viruses in the era of globalisation.全球化时代的新兴和再发病毒
Blood Transfus. 2009 Jul;7(3):167-71. doi: 10.2450/2009.0076-08.

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

作者信息

Di Minno Giovanni, Canaro Mariana, Ironside James W, Navarro David, Perno Carlo Federico, Tiede Andreas, Gürtler Lutz

出版信息

Haematologica. 2013 Oct;98(10):1495-8. doi: 10.3324/haematol.2013.084145.

DOI:10.3324/haematol.2013.084145
PMID:24091928
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3789452/
Abstract
摘要